MAPT and Alzheimer disease: Indeed, it has been previously demonstrated that pathological forms of tau (associated with Alzheimer’s disease and various tauopathies) and αSyn (associated with Parkinson’s disease and other synucleinopathies) can hinder the efficacy of the proteasome [9–16].